These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
570 related articles for article (PubMed ID: 31152925)
1. Improving breast cancer therapy using doxorubicin loaded solid lipid nanoparticles: Synthesis of a novel arginine-glycine-aspartic tripeptide conjugated, pH sensitive lipid and evaluation of the nanomedicine in vitro and in vivo. Zheng G; Zheng M; Yang B; Fu H; Li Y Biomed Pharmacother; 2019 Aug; 116():109006. PubMed ID: 31152925 [TBL] [Abstract][Full Text] [Related]
2. pH-Responsive therapeutic solid lipid nanoparticles for reducing P-glycoprotein-mediated drug efflux of multidrug resistant cancer cells. Chen HH; Huang WC; Chiang WH; Liu TI; Shen MY; Hsu YH; Lin SC; Chiu HC Int J Nanomedicine; 2015; 10():5035-48. PubMed ID: 26346762 [TBL] [Abstract][Full Text] [Related]
3. Breast cancer targeted chemotherapy based on doxorubicin-loaded bombesin peptide modified nanocarriers. Wang C; Sun X; Wang K; Wang Y; Yang F; Wang H Drug Deliv; 2016 Oct; 23(8):2697-2702. PubMed ID: 26203692 [TBL] [Abstract][Full Text] [Related]
4. Robust, active tumor-targeting and fast bioresponsive anticancer nanotherapeutics based on natural endogenous materials. Sun B; Deng C; Meng F; Zhang J; Zhong Z Acta Biomater; 2016 Nov; 45():223-233. PubMed ID: 27576338 [TBL] [Abstract][Full Text] [Related]
5. Reversal of doxorubicin resistance in breast cancer by mitochondria-targeted pH-responsive micelles. Yu P; Yu H; Guo C; Cui Z; Chen X; Yin Q; Zhang P; Yang X; Cui H; Li Y Acta Biomater; 2015 Mar; 14():115-24. PubMed ID: 25498306 [TBL] [Abstract][Full Text] [Related]
6. Dual-responsive mPEG-PLGA-PGlu hybrid-core nanoparticles with a high drug loading to reverse the multidrug resistance of breast cancer: an in vitro and in vivo evaluation. Xu H; Yang D; Cai C; Gou J; Zhang Y; Wang L; Zhong H; Tang X Acta Biomater; 2015 Apr; 16():156-68. PubMed ID: 25662165 [TBL] [Abstract][Full Text] [Related]
7. Micelles of d-α-Tocopheryl Polyethylene Glycol 2000 Succinate (TPGS 2K) for Doxorubicin Delivery with Reversal of Multidrug Resistance. Hao T; Chen D; Liu K; Qi Y; Tian Y; Sun P; Liu Y; Li Z ACS Appl Mater Interfaces; 2015 Aug; 7(32):18064-75. PubMed ID: 26214761 [TBL] [Abstract][Full Text] [Related]
8. Lung cancer therapy using doxorubicin and curcumin combination: Targeted prodrug based, pH sensitive nanomedicine. Hong Y; Che S; Hui B; Yang Y; Wang X; Zhang X; Qiang Y; Ma H Biomed Pharmacother; 2019 Apr; 112():108614. PubMed ID: 30798129 [TBL] [Abstract][Full Text] [Related]
9. Delivery of mitochondriotropic doxorubicin derivatives using self-assembling hyaluronic acid nanocarriers in doxorubicin-resistant breast cancer. Liu HN; Guo NN; Guo WW; Huang-Fu MY; Vakili MR; Chen JJ; Xu WH; Wei QC; Han M; Lavasanifar A; Gao JQ Acta Pharmacol Sin; 2018 Oct; 39(10):1681-1692. PubMed ID: 29849132 [TBL] [Abstract][Full Text] [Related]
10. Dual pH-responsive multifunctional nanoparticles for targeted treatment of breast cancer by combining immunotherapy and chemotherapy. Liu Y; Qiao L; Zhang S; Wan G; Chen B; Zhou P; Zhang N; Wang Y Acta Biomater; 2018 Jan; 66():310-324. PubMed ID: 29129789 [TBL] [Abstract][Full Text] [Related]
11. Surface modification of doxorubicin-loaded nanoparticles based on polydopamine with pH-sensitive property for tumor targeting therapy. Bi D; Zhao L; Yu R; Li H; Guo Y; Wang X; Han M Drug Deliv; 2018 Nov; 25(1):564-575. PubMed ID: 29457518 [TBL] [Abstract][Full Text] [Related]
12. Modified methods of nanoparticles synthesis in pH-sensitive nano-carriers production for doxorubicin delivery on MCF-7 breast cancer cell line. Hamidu A; Mokrish A; Mansor R; Razak ISA; Danmaigoro A; Jaji AZ; Bakar ZA Int J Nanomedicine; 2019; 14():3615-3627. PubMed ID: 31190815 [No Abstract] [Full Text] [Related]
13. PEGylated Poly(α-lipoic acid) Loaded with Doxorubicin as a pH and Reduction Dual Responsive Nanomedicine for Breast Cancer Therapy. Yang H; Shen W; Liu W; Chen L; Zhang P; Xiao C; Chen X Biomacromolecules; 2018 Nov; 19(11):4492-4503. PubMed ID: 30346147 [TBL] [Abstract][Full Text] [Related]
14. Nanostructured lipid carriers co-delivering lapachone and doxorubicin for overcoming multidrug resistance in breast cancer therapy. Li X; Jia X; Niu H Int J Nanomedicine; 2018; 13():4107-4119. PubMed ID: 30034236 [TBL] [Abstract][Full Text] [Related]
15. A glutathione-responsive sulfur dioxide polymer prodrug as a nanocarrier for combating drug-resistance in cancer chemotherapy. Shen W; Liu W; Yang H; Zhang P; Xiao C; Chen X Biomaterials; 2018 Sep; 178():706-719. PubMed ID: 29433753 [TBL] [Abstract][Full Text] [Related]
16. Mitochondrial Targeted Doxorubicin-Triphenylphosphonium Delivered by Hyaluronic Acid Modified and pH Responsive Nanocarriers to Breast Tumor: in Vitro and in Vivo Studies. Liu HN; Guo NN; Wang TT; Guo WW; Lin MT; Huang-Fu MY; Vakili MR; Xu WH; Chen JJ; Wei QC; Han M; Lavasanifar A; Gao JQ Mol Pharm; 2018 Mar; 15(3):882-891. PubMed ID: 29357260 [TBL] [Abstract][Full Text] [Related]
17. Co-delivery of DOX and PDTC by pH-sensitive nanoparticles to overcome multidrug resistance in breast cancer. Cheng X; Li D; Sun M; He L; Zheng Y; Wang X; Tang R Colloids Surf B Biointerfaces; 2019 Sep; 181():185-197. PubMed ID: 31132609 [TBL] [Abstract][Full Text] [Related]
18. Combination lung cancer chemotherapy: Design of a pH-sensitive transferrin-PEG-Hz-lipid conjugate for the co-delivery of docetaxel and baicalin. Li S; Wang L; Li N; Liu Y; Su H Biomed Pharmacother; 2017 Nov; 95():548-555. PubMed ID: 28869892 [TBL] [Abstract][Full Text] [Related]
19. Superparamagnetic iron oxide nanoparticles conjugated with folic acid for dual target-specific drug delivery and MRI in cancer theranostics. Huang Y; Mao K; Zhang B; Zhao Y Mater Sci Eng C Mater Biol Appl; 2017 Jan; 70(Pt 1):763-771. PubMed ID: 27770953 [TBL] [Abstract][Full Text] [Related]
20. Platelet-camouflaged nanococktail: Simultaneous inhibition of drug-resistant tumor growth and metastasis via a cancer cells and tumor vasculature dual-targeting strategy. Jing L; Qu H; Wu D; Zhu C; Yang Y; Jin X; Zheng J; Shi X; Yan X; Wang Y Theranostics; 2018; 8(10):2683-2695. PubMed ID: 29774068 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]